• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝利尤单抗成功治疗系统性红斑狼疮性胸膜心包炎。

Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.

作者信息

Carrión-Barberà Irene, Salman-Monte Tarek Carlos, Castell Sonia, Castro-Domínguez Francisco, Ojeda Fabiola, Monfort Jordi

机构信息

Department of Rheumatology, Hospital del Mar, Barcelona, Spain.

出版信息

Eur J Rheumatol. 2019 May 20;6(3):150-152. doi: 10.5152/eurjrheum.2019.17169. Print 2019 Jul.

DOI:10.5152/eurjrheum.2019.17169
PMID:31364982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6668643/
Abstract

Systemic lupus erythematosus (SLE) is characterized by a wide variety of manifestations and a difficult disease control in some patients. We present the case of a 51-year-old woman who presented with a flare of SLE including arthritis and pleuropericarditis that responded to neither leflunomide, methotrexate, nor high doses of prednisone. After initiating treatment with belimumab, the patient experienced a quick and notorious improvement. She remains stable to this day while continuing belimumab therapy.

摘要

系统性红斑狼疮(SLE)的特点是表现形式多种多样,且部分患者的病情难以控制。我们报告一例51岁女性患者,其SLE病情发作,伴有关节炎和胸膜心包炎,来氟米特、甲氨蝶呤及大剂量泼尼松治疗均无效。使用贝利尤单抗治疗后,患者病情迅速且显著改善。至今继续使用贝利尤单抗治疗,病情保持稳定。

相似文献

1
Successful treatment of systemic lupus erythematosus pleuropericarditis with belimumab.贝利尤单抗成功治疗系统性红斑狼疮性胸膜心包炎。
Eur J Rheumatol. 2019 May 20;6(3):150-152. doi: 10.5152/eurjrheum.2019.17169. Print 2019 Jul.
2
Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.贝利尤单抗治疗停药后系统性红斑狼疮病情加重。
Scand J Rheumatol. 2016;45(2):103-6. doi: 10.3109/03009742.2015.1074277. Epub 2015 Oct 29.
3
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.贝利尤单抗对活动性系统性红斑狼疮患者发作率和预期损伤进展的影响。
Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123. doi: 10.1002/acr.22971. Epub 2016 Nov 18.
4
Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.孕期全程使用贝利尤单抗治疗活动性系统性红斑狼疮:一例病例报告
Semin Arthritis Rheum. 2014 Oct;44(2):195-7. doi: 10.1016/j.semarthrit.2014.05.006. Epub 2014 Jun 6.
5
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.两名系统性红斑狼疮(SLE)患者在开始使用贝利尤单抗治疗后不久出现了狼疮性肾炎。
Semin Arthritis Rheum. 2017 Jun;46(6):788-790. doi: 10.1016/j.semarthrit.2016.09.006. Epub 2016 Sep 28.
6
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.在临床实践环境中接受贝利尤单抗治疗的系统性红斑狼疮患者的临床结局:瑞士观察性研究结果的回顾性分析
Swiss Med Wkly. 2019 Mar 10;149:w20022. doi: 10.4414/smw.2019.20022. eCollection 2019 Feb 25.
7
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.一项在中国、日本和韩国进行的关键的 III 期、随机、安慰剂对照研究评估了贝利尤单抗治疗系统性红斑狼疮患者的疗效。
Ann Rheum Dis. 2018 Mar;77(3):355-363. doi: 10.1136/annrheumdis-2017-211631. Epub 2018 Jan 2.
8
A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.皮下注射贝利木单抗治疗系统性红斑狼疮患者安全性和有效性的6个月开放标签扩展研究。
Lupus. 2018 Aug;27(9):1489-1498. doi: 10.1177/0961203318777634. Epub 2018 May 28.
9
Belimumab: review of use in systemic lupus erythematosus.贝利尤单抗:治疗系统性红斑狼疮的应用评价。
Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30.
10
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.贝利尤单抗在学术临床实践中治疗系统性红斑狼疮的安全性和有效性。
J Rheumatol. 2015 Dec;42(12):2288-95. doi: 10.3899/jrheum.150470. Epub 2015 Nov 1.

引用本文的文献

1
Management of Cardiac Tamponade During Systemic Lupus Erythematosus Flare with Significant Pericardial Effusion: A Case Report.系统性红斑狼疮发作伴大量心包积液时心脏压塞的处理:一例报告
Am J Case Rep. 2025 Aug 23;26:e947859. doi: 10.12659/AJCR.947859.
2
Pulmonary Involvement in Systemic Lupus Erythematosus: A Potentially Overlooked Condition.系统性红斑狼疮的肺部受累:一种可能被忽视的病症。
Biomedicines. 2025 Jun 16;13(6):1485. doi: 10.3390/biomedicines13061485.
3
Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.在西班牙真实世界中使用贝利尤单抗:一项关于 SLE 患者特征的范围综述。
Clin Rheumatol. 2022 Nov;41(11):3373-3382. doi: 10.1007/s10067-022-06287-9. Epub 2022 Jul 23.
4
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review.系统性红斑狼疮和干燥综合征肺部受累的诊断与管理:文献综述
Ther Adv Musculoskelet Dis. 2021 Sep 30;13:1759720X211040696. doi: 10.1177/1759720X211040696. eCollection 2021.
5
Peripheral blood perfusion in patients with systemic lupus erythematosus and in primary Raynaud's phenomenon.系统性红斑狼疮患者及原发性雷诺现象患者的外周血灌注
Eur J Rheumatol. 2021 Jan;8(1):7-11. doi: 10.5152/eurjrheum.2020.20027. Epub 2020 Nov 11.

本文引用的文献

1
Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital.贝利尤单抗治疗系统性红斑狼疮:地区医院临床实践经验
Reumatol Clin (Engl Ed). 2020 Mar-Apr;16(2 Pt 2):188-189. doi: 10.1016/j.reuma.2018.02.004. Epub 2018 Mar 17.
2
When to use belimumab in SLE.系统性红斑狼疮何时使用贝利尤单抗。
Expert Rev Clin Immunol. 2017 Aug;13(8):737-740. doi: 10.1080/1744666X.2017.1324784. Epub 2017 May 5.
3
Belimumab in the management of systemic lupus erythematosus - an update.贝利尤单抗治疗系统性红斑狼疮的最新进展
Expert Opin Biol Ther. 2017 Jul;17(7):901-908. doi: 10.1080/14712598.2017.1324846. Epub 2017 May 16.
4
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.国际和多学科专家关于生物制剂在系统性红斑狼疮中应用的建议。
Autoimmun Rev. 2017 Jun;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011. Epub 2017 Apr 18.
5
The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study.系统性红斑狼疮患者浆膜炎的患病率及危险因素:一项横断面研究。
Rheumatol Int. 2017 Feb;37(2):305-311. doi: 10.1007/s00296-016-3630-0. Epub 2016 Dec 20.
6
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.生物治疗系统性红斑狼疮的成败:批判性分析。
J Autoimmun. 2016 Nov;74:94-105. doi: 10.1016/j.jaut.2016.06.014. Epub 2016 Jun 30.
7
Chinese SLE Treatment and Research group (CSTAR) registry VII: prevalence and clinical significance of serositis in Chinese patients with systemic lupus erythematosus.中国系统性红斑狼疮治疗与研究协作组(CSTAR)注册研究VII:中国系统性红斑狼疮患者浆膜炎的患病率及临床意义
Lupus. 2016 May;25(6):652-7. doi: 10.1177/0961203315625460. Epub 2016 Jan 12.
8
Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.贝利尤单抗在两名托珠单抗治疗期间发生狼疮发作的系统性红斑狼疮患者中的成功应用。
Lupus. 2014 Apr;23(4):428-30. doi: 10.1177/0961203314520844. Epub 2014 Jan 30.
9
SER consensus statement on the use of biologic therapy for systemic lupus erythematosus.系统性红斑狼疮生物治疗使用的SER共识声明。
Reumatol Clin. 2013 Sep-Oct;9(5):281-96. doi: 10.1016/j.reuma.2013.04.001. Epub 2013 Jul 17.
10
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.贝利尤单抗治疗系统性红斑狼疮:高疾病活动度预测应答。
Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.